Merck's new drug ENFLONSIA has received FDA approval for preventing RSV in newborns and infants, promising significant reductions in hospitalizations and severe respiratory illness. This long-acting monoclonal antibody offers hope for parents facing RSV season challenges.
A groundbreaking study reveals that combining Trodelvy and Keytruda reduces tumor progression risk by over a third in aggressive breast cancer cases, paving the way for new treatment options.
